The Lancet volume 358, issue 9286, P958-965 2001 DOI: 10.1016/s0140-6736(01)06102-5

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

Michael P Manns, John G McHutchison, Stuart C Gordon, Vinod K Rustgi, Mitchell Shiffman, Robert Reindollar, Zachary D Goodman, Kenneth Koury, Mei-Hsiu Ling, Janice K Albrecht
Abstract: In patients with chronic hepatitis C, the most effective therapy is the combination of peginterferon alfa-2b 1.5 microg/kg per week plus ribavirin. The benefit is mostly achieved in patients with HCV genotype 1 infections.
x

Classification

227
4,541
61

Paper Sections

0
0
0
0
0